Budde, Klemens; Becker, Thomas; Arns, Wolfgang; Sommerer, Claudia; Reinke, Petra; Eisenberger, Ute; Kramer, Stefan; Fischer, Wolfgang; Gschaidmeier, Harald; Pietruck, Frank; ZEUS Study Investigators, (2011). Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, 377(9768), pp. 837-47. London: Elsevier 10.1016/S0140-6736(10)62318-5
Full text not available from this repository. (Request a copy)Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in kidney transplantation. Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension |
UniBE Contributor: |
Eisenberger, Ute |
ISSN: |
0140-6736 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:25 |
Last Modified: |
05 Dec 2022 14:07 |
Publisher DOI: |
10.1016/S0140-6736(10)62318-5 |
PubMed ID: |
21334736 |
Web of Science ID: |
000288628500031 |
URI: |
https://boris.unibe.ch/id/eprint/8977 (FactScience: 214637) |
Actions (login required)
 |
Edit item |